1Landi L, Tiseo M, Chiari R, et al. Activity of the EGFR- HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR ty- rosine kinase inhibitors [J]. Ctin Lung Cancer, 2014, 15 (6) : 411-417.
2Assenat E, Azria D, Mollevi C, et al. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY" phase 1-2 trial [J]. On- cotarget, 2015, 6 (14) : 12 796-12 808.
3Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas [J]. BMCCancer, 2010, 10 (33): 631-644.
4Ki J, Arumugam P, Song JM. TIRF high-content assay development for the evaluation of drug efficacy of chemo- therapeutic agents against EGFR-/HER2-positive breast cancer cell lines [J]. Anal Bioanal Chem, 2016, 19 ( 11 ) : 1-6.
5Saxena R, Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective [J]. Med Res Rev, 2012, 32 ( 1 ) : 166-215.
6Advani PP, Crozier JA, Perez EA. HER2 testing and its predictive utility in anti-HER2 breast cancer therapy [J]. BiomarkMed, 2015, 9(1): 35-49.
7Labonte MJ, Wilson PM:, Fazzone W, et al. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models [J]. Annu Rev Mi- crobiol, 2011, 71 (10): 3635-3648.
8Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase[J]. Science, 1994, 265 (5175) : 1093-1095.
9Wainberg ZA, Anghel A, Desai A J, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is syner- gistic with trastuzumab in vitro and in vivo [J]. Clin Cancer Res, 2010, 16 (5) : 1509-1519.
10Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small- cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy ( LUX-Lung 1 ) ~ a phase 2b/3 randomised trial [J]. Lancet Oncol, 2012, 13 (5) : 528-538.
